Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | KCNK2 | O95069 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | GFER | P55789 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | PLK1 | P53350 | 1/20 | 0.48 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.48 |
| ▸ | AKR1C3 | P42330 | 7/20 | 0.47 |
| ▸ | AKR1C2 | P52895 | 7/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27969536 | 0.89 | KDM4E (0.51) | MAPTKCNK2POLBCA2HPGD | |
| SCHEMBL31619048 | 0.87 | KMT2A (0.52) | MAPTMEN1LMNAKMT2ACA2 | |
| SCHEMBL1767849 | 0.87 | KMT2A (0.52) | MAPTMEN1LMNAKMT2ACA2 | |
| SCHEMBL2795277 | 0.85 | NPC1 (0.46) | MAPTMEN1LMNAKMT2APOLB | |
| SCHEMBL31372038 | 0.85 | NPC1 (0.46) | MAPTMEN1LMNAKMT2APOLB | |
| SCHEMBL687475 | 0.85 | IGF2BP2 (0.58) | MAPTKCNK2LMNAPOLBKDM4E | |
| SCHEMBL27852761 | 0.84 | MEN1 (0.56) | MAPTMEN1KMT2AHPGDGFER | |
| SCHEMBL7953540 | 0.83 | STS (0.43) | MAPTLMNASMN1; SMN2HPGDKDM4E | |
| SCHEMBL24253966 | 0.82 | POLB (0.56) | MAPTMEN1KMT2APOLBCA2 | |
| SCHEMBL2589170 | 0.82 | ALDH1A1 (0.63) | MAPTMEN1LMNAKMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7576241-B2 | Derivatives of amidines, their preparation, their use as medicaments and the pharmaceutical compositions containing them | IPSEN PHARMA S.A.S. (FR) | 2009-08-18 | — | — | US | disclosed |
| US-7473779-B2 | Derivatives of amidines, their preparation, their use as medicaments and the pharmaceutical compositions containing them | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2009-01-06 | — | — | US | disclosed |
| US-20060084667-A1 | New derivatives of amidines, their preparation, their use as medicaments and the pharmaceutical compositions containing them | IPSEN PHARMA S.A.S. (FR) | 2006-04-20 | — | — | US | disclosed |
| US-20050261269-A1 | New derivatives of amidines, their preparation, their use as medicaments and the pharmaceutical compositions containing them | SOCIETE DE CONSEILS DE RECHERCHES ET D' APPLICATIONS SCIENTIFIQUES (S.C.R.A.S) | 2005-11-24 | — | — | US | disclosed |
| CN-1148367-C | Amidine derivatives, their preparation and application as medicines and pharmaceutical compositions containing same | ��ѧ�о���Ӧ����ѯ��˾ | 2004-05-05 | — | — | CN | disclosed |
| US-6653312-B1 | Such as 3-((3-((amino(2-thienyl)methylideneamino)-benzyl)-amino)-N-(1- methyl-2,3-dihydro-1H-indol-5-yl)propanamide; NO-synthase enzyme inhibitors | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2003-11-25 | — | — | US | disclosed |
| CN-1324353-A | Amidine derivatives, their preparation and application as medicines and pharmaceutical compositions containing same | SOD CONSEILS RECH APPLIC (FR) | 2001-11-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261269-A1 | New derivatives of amidines, their preparation, their use as medicaments and the pharmaceutical compositions containing them | NOS2, NOS1, NOS3 | MAPT 2048/4885KCNK2 2984/4885MEN1 2716/4885 |
| US-20060084667-A1 | New derivatives of amidines, their preparation, their use as medicaments and the pharmaceutical compositions containing them | ADM2, NUP155, ABCG2 | MAPT 1719/4885KCNK2 3078/4885MEN1 243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.